Varlilumab
A monoclonal antibody used in cancer immunotherapy
| Varlilumab | |
|---|---|
| [[File:|frameless|220px|alt=|]] | |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | 1263383-89-0 |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Varlilumab (also known as CDX-1127) is a monoclonal antibody that targets the CD27 receptor, a member of the tumor necrosis factor receptor superfamily. It is being investigated for its potential use in cancer immunotherapy.
Mechanism of Action
Varlilumab is designed to modulate the immune system by targeting CD27, a co-stimulatory molecule found on T cells. CD27 plays a crucial role in the activation and survival of T cells, which are essential components of the adaptive immune response. By binding to CD27, varlilumab can enhance T cell activation and proliferation, potentially leading to a more robust anti-tumor immune response.
Clinical Development
Varlilumab is currently undergoing clinical trials to evaluate its efficacy and safety in treating various types of cancer, including lymphoma, melanoma, and renal cell carcinoma. Early-phase clinical trials have shown promising results, with some patients experiencing tumor shrinkage and prolonged disease stabilization.
Potential Benefits
The use of varlilumab in cancer therapy is based on its ability to enhance the body's immune response against tumor cells. By activating T cells, varlilumab may help overcome the immunosuppressive environment often found in tumors, allowing the immune system to effectively target and destroy cancer cells.
Side Effects
As with other immunotherapies, varlilumab can cause immune-related adverse effects. These may include cytokine release syndrome, autoimmune reactions, and other inflammatory responses. Close monitoring and management of these side effects are essential during treatment.
Research and Future Directions
Ongoing research is focused on optimizing the use of varlilumab in combination with other therapies, such as checkpoint inhibitors and chemotherapy. These combination strategies aim to enhance the overall efficacy of cancer treatment by leveraging multiple mechanisms of action.
Also see
This article is a immunology stub. You can help WikiMD by expanding it!
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
